{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["29(1)"],"submitter":["Friedrich NA"],"pubmed_abstract":["<h4>Background</h4>For metastatic and certain advanced prostate cancer (PC), guidelines support intensified androgen deprivation therapy (ADT) as first-line (1 L) systemic treatment. However, some patients receive ADT alone, leading to tumor progression requiring 2<sup>nd</sup> line therapy. Despite racial disparities in PC outcomes, there are no population-level studies assessing racial differences in time to subsequent treatment after 1 L ADT.<h4>Methods</h4>We performed a retrospective population-level analysis to assess the association between race and time to subsequent treatment after ADT in the Veterans Affairs Health Care System. Primary outcome was time from ADT monotherapy to subsequent treatment, defined as receipt of androgen receptor pathway inhibitor (ARPI), non-steroidal fir"],"journal":["Prostate cancer and prostatic diseases"],"pagination":["103-110"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12909120"],"repository":["biostudies-literature"],"pubmed_title":["Assessing racial differences in time to subsequent treatment following androgen deprivation therapy among Veterans with prostate cancer."],"pmcid":["PMC12909120"],"pubmed_authors":["Janes JL","De Hoedt AM","Gandhi R","Parrish J","Freedland SJ","Fallick M","Tatonetti NP","Pruett J","Hong A","Friedrich NA"],"additional_accession":[]},"is_claimable":false,"name":"Assessing racial differences in time to subsequent treatment following androgen deprivation therapy among Veterans with prostate cancer.","description":"<h4>Background</h4>For metastatic and certain advanced prostate cancer (PC), guidelines support intensified androgen deprivation therapy (ADT) as first-line (1 L) systemic treatment. However, some patients receive ADT alone, leading to tumor progression requiring 2<sup>nd</sup> line therapy. Despite racial disparities in PC outcomes, there are no population-level studies assessing racial differences in time to subsequent treatment after 1 L ADT.<h4>Methods</h4>We performed a retrospective population-level analysis to assess the association between race and time to subsequent treatment after ADT in the Veterans Affairs Health Care System. Primary outcome was time from ADT monotherapy to subsequent treatment, defined as receipt of androgen receptor pathway inhibitor (ARPI), non-steroidal fir","dates":{"release":"2026-01-01T00:00:00Z","publication":"2026 Mar","modification":"2026-07-16T00:30:09.514Z","creation":"2026-07-09T10:26:30.303Z"},"accession":"S-EPMC12909120","cross_references":{"pubmed":["40615515"],"doi":["10.1038/s41391-025-00995-4"]}}